Research programme: hepatitis C therapeutics - Medivir

Drug Profile

Research programme: hepatitis C therapeutics - Medivir

Alternative Names: MIV-802; Nucleotide polymerase inhibitors - Medivir AB

Latest Information Update: 04 May 2017

Price : $50

At a glance

  • Originator Medivir AB
  • Class Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Nucleotidyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Hepatitis C

Most Recent Events

  • 28 Apr 2017 MIV 802 licensed to Trek Therapeutics worldwide, including China, Hong Kong, Taiwan and Macau
  • 05 May 2015 Research programme: hepatitis C therapeutics - Medivir is available for licensing as of 05 May 2015.
  • 22 Dec 2014 Preclinical development is ongoing in Sweden
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top